TY - JOUR
T1 - Proceedings of the Clinical Microbiology Open 2018 and 2019 - a Discussion about Emerging Trends, Challenges, and the Future of Clinical Microbiology
AU - the American Society for Microbiology (ASM) Clinical and Public Health Microbiology Committee and the ASM Corporate Council
AU - Doern, Christopher D.
AU - Miller, Melissa B.
AU - Alby, Kevin
AU - Bachman, Michael A.
AU - Brecher, Stephen M.
AU - Casiano-Colon, Aida
AU - Couturier, Marc Roger
AU - Johnson, J. Kristie
AU - Kirby, James E.
AU - McElvania, Erin
AU - Newton, Duane W.
AU - Nolte, Frederick S.
AU - Pancholi, Preeti
AU - McNult, Peggy
AU - Dharmarha, Vaishali
AU - Dunbar, Sherry
AU - Atrzadeh, Faranak
AU - Bambach, Adrienne
AU - Cárdenas, Ana María
AU - Elliott, Sarah
AU - Filkins, Laura
AU - Flayhart, Diane
AU - Graf, Erin
AU - Gross, Mona
AU - Harrington, Amanda
AU - Henderson-Samuel, Triona
AU - Hodinka, Richard
AU - Hoon, Kelly
AU - Kuchta, Alison
AU - Lesho, Matthew
AU - Lingenfelter, Beth
AU - Long, S. Wesley
AU - Martino, Ray
AU - McCombs, Erin
AU - Mitchell, Stephanie
AU - Mostafa, Heba
AU - O'Brien, Scott
AU - Patel, Jean
AU - Patel, Robin
AU - Powell, Robyn
AU - Qi, Chao
AU - Rhodes, Paul
AU - Sharp, Susan
AU - Sharples, Norman
AU - Stevenson, Wade
AU - Svarczkopf, Benjamin
AU - Tenover, Fred
AU - Whitfield, Natalie
AU - Zhang, Sean
N1 - Funding Information:
Overall, CMO 2018 accomplished its goal: to establish a unique forum for conversations between industry partners and microbiologists to help chart the course for our profession. Based on the success of this meeting, a second CMO (CMO 2019) was held on December 5th and 6th, 2019, in Palm Springs, California. The format was largely unchanged from CMO 2018 with the same guiding principle, i.e., to foster constructive conversation between industry and the laboratory to move diagnostic microbiology forward. The meeting was made possible by the support of ASM and the Corporate Council, which included industry participation from Beckman Coulter, Becton, Dickinson Life Sciences, BioFire Diagnostics, LLC, Cepheid, Copan Diagnostics, Inc., Curetis USA Inc., Diasorin Molecular, LLC, GenMark Diagnostics, Inc., Illumina, Inc, Luminex Corporation, Roche Molecular Systems, and Specific Diagnostics. In total, 48 leaders in the field participated, 23 from clinical and public health laboratories, 23 from industry, 1 from the CDC, and 1 from the FDA.
Publisher Copyright:
© 2022 American Society for Microbiology. All rights reserved.
PY - 2022/7
Y1 - 2022/7
N2 - Clinical Microbiology Open (CMO), a meeting supported by the American Society for Microbiology's Clinical and Public Health Microbiology Committee (CPHMC) and Corporate Council, provides a unique interactive platform for leaders from diagnostic microbiology laboratories, industry, and federal agencies to discuss the current and future state of the clinical microbiology laboratory. The purpose is to leverage the group's diverse views and expertise to address critical challenges, and discuss potential collaborative opportunities for diagnostic microbiology, through the utilization of varied resources. The first and second CMO meetings were held in 2018 and 2019, respectively. Discussions were focused on the diagnostic potential of innovative technologies and laboratory diagnostic stewardship, including expansion of next-generation sequencing into clinical diagnostics, improvement and advancement of molecular diagnostics, emerging diagnostics, including rapid antimicrobial susceptibility and point of care testing (POCT), harnessing big data through artificial intelligence, and staffing in the clinical microbiology laboratory. Shortly after CMO 2019, the coronavirus disease 2019 (COVID-19) pandemic further highlighted the need for the diagnostic microbiology community to work together to utilize and expand on resources to respond to the pandemic. The issues, challenges, and potential collaborative efforts discussed during the past two CMO meetings proved critical in addressing the COVID-19 response by diagnostic laboratories, industry partners, and federal organizations. Planning for a third CMO (CMO 2022) is underway and will transition from a discussion-based meeting to an action-based meeting. The primary focus will be to reflect on the lessons learned from the COVID-19 pandemic and better prepare for future pandemics.
AB - Clinical Microbiology Open (CMO), a meeting supported by the American Society for Microbiology's Clinical and Public Health Microbiology Committee (CPHMC) and Corporate Council, provides a unique interactive platform for leaders from diagnostic microbiology laboratories, industry, and federal agencies to discuss the current and future state of the clinical microbiology laboratory. The purpose is to leverage the group's diverse views and expertise to address critical challenges, and discuss potential collaborative opportunities for diagnostic microbiology, through the utilization of varied resources. The first and second CMO meetings were held in 2018 and 2019, respectively. Discussions were focused on the diagnostic potential of innovative technologies and laboratory diagnostic stewardship, including expansion of next-generation sequencing into clinical diagnostics, improvement and advancement of molecular diagnostics, emerging diagnostics, including rapid antimicrobial susceptibility and point of care testing (POCT), harnessing big data through artificial intelligence, and staffing in the clinical microbiology laboratory. Shortly after CMO 2019, the coronavirus disease 2019 (COVID-19) pandemic further highlighted the need for the diagnostic microbiology community to work together to utilize and expand on resources to respond to the pandemic. The issues, challenges, and potential collaborative efforts discussed during the past two CMO meetings proved critical in addressing the COVID-19 response by diagnostic laboratories, industry partners, and federal organizations. Planning for a third CMO (CMO 2022) is underway and will transition from a discussion-based meeting to an action-based meeting. The primary focus will be to reflect on the lessons learned from the COVID-19 pandemic and better prepare for future pandemics.
KW - COVID
KW - next-generation sequencing
KW - pandemic
KW - point of care testing
KW - staffing
KW - stewardship
KW - utilization
UR - http://www.scopus.com/inward/record.url?scp=85134832466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134832466&partnerID=8YFLogxK
U2 - 10.1128/jcm.00092-22
DO - 10.1128/jcm.00092-22
M3 - Review article
C2 - 35638361
AN - SCOPUS:85134832466
SN - 0095-1137
VL - 60
JO - Journal of clinical microbiology
JF - Journal of clinical microbiology
IS - 7
ER -